{
    "amitriptyline": {
        "0": {
            "id": 5873983,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5873984,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5873985,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5873986,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "4": {
            "id": 5873987,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "5": {
            "id": 5873988,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "6": {
            "id": 5873989,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "7": {
            "id": 5873990,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "8": {
            "id": 5873991,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "9": {
            "id": 5873992,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "10": {
            "id": 5873993,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "11": {
            "id": 5873994,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "12": {
            "id": 5873995,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "13": {
            "id": 5873996,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "14": {
            "id": 5873997,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "15": {
            "id": 5873998,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "16": {
            "id": 5873999,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "17": {
            "id": 5874000,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "18": {
            "id": 5874001,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "19": {
            "id": 5874002,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "20": {
            "id": 5874003,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "21": {
            "id": 5874004,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "22": {
            "id": 5874005,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "23": {
            "id": 5873960,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "24": {
            "id": 5873961,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "25": {
            "id": 5873962,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "26": {
            "id": 5873963,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "27": {
            "id": 5873964,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "28": {
            "id": 5873965,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "29": {
            "id": 5873966,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "30": {
            "id": 5873967,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "31": {
            "id": 5873968,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "32": {
            "id": 5873969,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "33": {
            "id": 5873970,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "34": {
            "id": 5873971,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "35": {
            "id": 5873972,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "36": {
            "id": 5873973,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "37": {
            "id": 5873974,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "38": {
            "id": 5873975,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "39": {
            "id": 5873976,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "40": {
            "id": 5873977,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "41": {
            "id": 5873978,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "42": {
            "id": 5873979,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "43": {
            "id": 5873980,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "44": {
            "id": 5873981,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "45": {
            "id": 5873982,
            "guidelineid": 100414,
            "drugid": "RxNorm:704",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "citalopram": {
        "0": {
            "id": 5874254,
            "guidelineid": 100413,
            "drugid": "RxNorm:2556",
            "implications": {
                "CYP2C19": "Increased metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 rapid and normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
            },
            "drugrecommendation": "Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.",
            "classification": "Strong",
            "phenotypes": {
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "population": "general",
            "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5874255,
            "guidelineid": 100413,
            "drugid": "RxNorm:2556",
            "implications": {
                "CYP2C19": "Increase in metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2C19": "Rapid Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Rapid Metabolizer"
            },
            "population": "general",
            "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "clopidogrel": {
        "0": {
            "id": 5874478,
            "guidelineid": 100411,
            "drugid": "RxNorm:32968",
            "implications": {
                "CYP2C19": "Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"
            },
            "drugrecommendation": "If considering clopidogrel, use at standard dose (75 mg/day)",
            "classification": "Strong",
            "phenotypes": {
                "CYP2C19": "Normal Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Normal Metabolizer"
            },
            "population": "CVI ACS PCI ",
            "comments": "For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5874486,
            "guidelineid": 100411,
            "drugid": "RxNorm:32968",
            "implications": {
                "CYP2C19": "Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"
            },
            "drugrecommendation": "If considering clopidogrel, use at standard dose (75 mg/day)",
            "classification": "Strong",
            "phenotypes": {
                "CYP2C19": "Normal Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Normal Metabolizer"
            },
            "population": "CVI non-ACS non-PCI",
            "comments": "For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5874494,
            "guidelineid": 100411,
            "drugid": "RxNorm:32968",
            "implications": {
                "CYP2C19": "Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"
            },
            "drugrecommendation": "If considering clopidogrel, use at standard dose (75 mg/day)",
            "classification": "Strong",
            "phenotypes": {
                "CYP2C19": "Normal Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Normal Metabolizer"
            },
            "population": "NVI",
            "comments": "For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5874479,
            "guidelineid": 100411,
            "drugid": "RxNorm:32968",
            "implications": {
                "CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
            },
            "drugrecommendation": "Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.",
            "classification": "Strong",
            "phenotypes": {
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "population": "CVI ACS PCI ",
            "comments": "For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "4": {
            "id": 5874487,
            "guidelineid": 100411,
            "drugid": "RxNorm:32968",
            "implications": {
                "CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "population": "CVI non-ACS non-PCI",
            "comments": "For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "5": {
            "id": 5874495,
            "guidelineid": 100411,
            "drugid": "RxNorm:32968",
            "implications": {
                "CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
            },
            "drugrecommendation": "Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "population": "NVI",
            "comments": "For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "escitalopram": {
        "0": {
            "id": 5874264,
            "guidelineid": 100413,
            "drugid": "RxNorm:321988",
            "implications": {
                "CYP2C19": "Normal metabolism"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose",
            "classification": "Strong",
            "phenotypes": {
                "CYP2C19": "Normal Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Normal Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5874265,
            "guidelineid": 100413,
            "drugid": "RxNorm:321988",
            "implications": {
                "CYP2C19": "Reduced metabolism when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "lansoprazole": {
        "0": {
            "id": 5875248,
            "guidelineid": 110076,
            "drugid": "RxNorm:17128",
            "implications": {
                "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5875249,
            "guidelineid": 110076,
            "drugid": "RxNorm:17128",
            "implications": {
                "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5875250,
            "guidelineid": 110076,
            "drugid": "RxNorm:17128",
            "implications": {
                "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5875251,
            "guidelineid": 110076,
            "drugid": "RxNorm:17128",
            "implications": {
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "omeprazole": {
        "0": {
            "id": 5875240,
            "guidelineid": 110076,
            "drugid": "RxNorm:7646",
            "implications": {
                "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5875241,
            "guidelineid": 110076,
            "drugid": "RxNorm:7646",
            "implications": {
                "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5875242,
            "guidelineid": 110076,
            "drugid": "RxNorm:7646",
            "implications": {
                "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5875243,
            "guidelineid": 110076,
            "drugid": "RxNorm:7646",
            "implications": {
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "pantoprazole": {
        "0": {
            "id": 5875256,
            "guidelineid": 110076,
            "drugid": "RxNorm:40790",
            "implications": {
                "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5875257,
            "guidelineid": 110076,
            "drugid": "RxNorm:40790",
            "implications": {
                "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5875258,
            "guidelineid": 110076,
            "drugid": "RxNorm:40790",
            "implications": {
                "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5875259,
            "guidelineid": 110076,
            "drugid": "RxNorm:40790",
            "implications": {
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "sertraline": {
        "0": {
            "id": 5875533,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "n/a",
                "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5875534,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5875535,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Rapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Rapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5875536,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
                "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "4": {
            "id": 5875537,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "5": {
            "id": 5875538,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
                "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Poor Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Poor Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "6": {
            "id": 5875539,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "n/a",
                "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Indeterminate",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Indeterminate",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "7": {
            "id": 5875540,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "8": {
            "id": 5875541,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "9": {
            "id": 5875542,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Rapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Rapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "10": {
            "id": 5875543,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "11": {
            "id": 5875544,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "12": {
            "id": 5875545,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Poor Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Poor Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "13": {
            "id": 5875546,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Indeterminate",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Indeterminate",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "14": {
            "id": 5875547,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "15": {
            "id": 5875548,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "16": {
            "id": 5875549,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Rapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Rapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "17": {
            "id": 5875550,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "18": {
            "id": 5875551,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "19": {
            "id": 5875552,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Poor Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Poor Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "20": {
            "id": 5875553,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Indeterminate",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Indeterminate",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "21": {
            "id": 5875557,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "22": {
            "id": 5875554,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2B6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "23": {
            "id": 5875555,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "24": {
            "id": 5875556,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Rapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Rapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "25": {
            "id": 5875558,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2B6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "26": {
            "id": 5875559,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2B6": "Poor Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Poor Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "27": {
            "id": 5875560,
            "guidelineid": 100413,
            "drugid": "RxNorm:36437",
            "implications": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2B6": "Indeterminate",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2B6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2B6": "Indeterminate",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "voriconazole": {
        "0": {
            "id": 5875895,
            "guidelineid": 100410,
            "drugid": "RxNorm:121243",
            "implications": {
                "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "pediatrics",
            "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5875903,
            "guidelineid": 100410,
            "drugid": "RxNorm:121243",
            "implications": {
                "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "adults",
            "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5875896,
            "guidelineid": 100410,
            "drugid": "RxNorm:121243",
            "implications": {
                "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
            },
            "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "pediatrics",
            "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5875904,
            "guidelineid": 100410,
            "drugid": "RxNorm:121243",
            "implications": {
                "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
            },
            "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "adults",
            "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "4": {
            "id": 5875897,
            "guidelineid": 100410,
            "drugid": "RxNorm:121243",
            "implications": {
                "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
            },
            "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "pediatrics",
            "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "5": {
            "id": 5875905,
            "guidelineid": 100410,
            "drugid": "RxNorm:121243",
            "implications": {
                "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
            },
            "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
            "classification": "Moderate",
            "phenotypes": {
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "adults",
            "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "6": {
            "id": 5875898,
            "guidelineid": 100410,
            "drugid": "RxNorm:121243",
            "implications": {
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Indeterminate"
            },
            "population": "pediatrics",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "7": {
            "id": 5875906,
            "guidelineid": 100410,
            "drugid": "RxNorm:121243",
            "implications": {
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {},
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Indeterminate"
            },
            "population": "adults",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "clomipramine": {
        "0": {
            "id": 5874270,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5874271,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5874272,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5874273,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "4": {
            "id": 5874306,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "5": {
            "id": 5874307,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "6": {
            "id": 5874308,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "7": {
            "id": 5874309,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "8": {
            "id": 5874310,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "9": {
            "id": 5874351,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "10": {
            "id": 5874360,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "11": {
            "id": 5874361,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "12": {
            "id": 5874362,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "13": {
            "id": 5874363,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "14": {
            "id": 5874364,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "15": {
            "id": 5874365,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "16": {
            "id": 5874366,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "17": {
            "id": 5874367,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "18": {
            "id": 5874368,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "19": {
            "id": 5874369,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "20": {
            "id": 5874370,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "21": {
            "id": 5874459,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "22": {
            "id": 5874468,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "23": {
            "id": 5874298,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "24": {
            "id": 5874299,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "25": {
            "id": 5874300,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "26": {
            "id": 5874301,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "27": {
            "id": 5874341,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "28": {
            "id": 5874342,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "29": {
            "id": 5874343,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "30": {
            "id": 5874344,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "31": {
            "id": 5874345,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "32": {
            "id": 5874358,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "33": {
            "id": 5874437,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "34": {
            "id": 5874438,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "35": {
            "id": 5874439,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "36": {
            "id": 5874440,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "37": {
            "id": 5874441,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "38": {
            "id": 5874442,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "39": {
            "id": 5874443,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "40": {
            "id": 5874444,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "41": {
            "id": 5874445,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "42": {
            "id": 5874446,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "43": {
            "id": 5874447,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "44": {
            "id": 5874466,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "45": {
            "id": 5874475,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "46": {
            "id": 5874278,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "47": {
            "id": 5874279,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "48": {
            "id": 5874280,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "49": {
            "id": 5874281,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "50": {
            "id": 5874316,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "51": {
            "id": 5874317,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "52": {
            "id": 5874318,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "53": {
            "id": 5874319,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "54": {
            "id": 5874320,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "55": {
            "id": 5874353,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "56": {
            "id": 5874382,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "57": {
            "id": 5874383,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "58": {
            "id": 5874384,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "59": {
            "id": 5874385,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "60": {
            "id": 5874386,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "61": {
            "id": 5874387,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "62": {
            "id": 5874388,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "63": {
            "id": 5874389,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "64": {
            "id": 5874390,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "65": {
            "id": 5874391,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "66": {
            "id": 5874392,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "67": {
            "id": 5874461,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "68": {
            "id": 5874470,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "69": {
            "id": 5874290,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "70": {
            "id": 5874291,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "71": {
            "id": 5874292,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "72": {
            "id": 5874293,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "73": {
            "id": 5874331,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "74": {
            "id": 5874332,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "75": {
            "id": 5874333,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "76": {
            "id": 5874334,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "77": {
            "id": 5874335,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "78": {
            "id": 5874356,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "79": {
            "id": 5874419,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "80": {
            "id": 5874415,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "81": {
            "id": 5874416,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "82": {
            "id": 5874417,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "83": {
            "id": 5874418,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "84": {
            "id": 5874420,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "85": {
            "id": 5874421,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "86": {
            "id": 5874422,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "87": {
            "id": 5874423,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "88": {
            "id": 5874424,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "89": {
            "id": 5874425,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "90": {
            "id": 5874464,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "91": {
            "id": 5874473,
            "guidelineid": 100414,
            "drugid": "RxNorm:2597",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "dexlansoprazole": {
        "0": {
            "id": 5874619,
            "guidelineid": 110076,
            "drugid": "RxNorm:816346",
            "implications": {
                "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5874620,
            "guidelineid": 110076,
            "drugid": "RxNorm:816346",
            "implications": {
                "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5874621,
            "guidelineid": 110076,
            "drugid": "RxNorm:816346",
            "implications": {
                "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
            },
            "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5874622,
            "guidelineid": 110076,
            "drugid": "RxNorm:816346",
            "implications": {
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "No Recommendation",
            "phenotypes": {
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "doxepin": {
        "0": {
            "id": 5874661,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5874623,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5874624,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5874625,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "4": {
            "id": 5874626,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "5": {
            "id": 5874662,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "6": {
            "id": 5874663,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "7": {
            "id": 5874659,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "8": {
            "id": 5874660,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "9": {
            "id": 5874704,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "10": {
            "id": 5874714,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "11": {
            "id": 5874713,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "12": {
            "id": 5874715,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "13": {
            "id": 5874716,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "14": {
            "id": 5874717,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "15": {
            "id": 5874718,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "16": {
            "id": 5874719,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "17": {
            "id": 5874720,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "18": {
            "id": 5874721,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "19": {
            "id": 5874722,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "20": {
            "id": 5874723,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "21": {
            "id": 5874812,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "22": {
            "id": 5874821,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "23": {
            "id": 5874651,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "24": {
            "id": 5874652,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "25": {
            "id": 5874653,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "26": {
            "id": 5874654,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "27": {
            "id": 5874694,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "28": {
            "id": 5874695,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "29": {
            "id": 5874696,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "30": {
            "id": 5874697,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "31": {
            "id": 5874698,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "32": {
            "id": 5874711,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "33": {
            "id": 5874790,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "34": {
            "id": 5874791,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "35": {
            "id": 5874792,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "36": {
            "id": 5874793,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "37": {
            "id": 5874794,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "38": {
            "id": 5874795,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "39": {
            "id": 5874796,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "40": {
            "id": 5874797,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "41": {
            "id": 5874798,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "42": {
            "id": 5874799,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "43": {
            "id": 5874800,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "44": {
            "id": 5874819,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "45": {
            "id": 5874828,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "46": {
            "id": 5874631,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "47": {
            "id": 5874632,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "48": {
            "id": 5874633,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "49": {
            "id": 5874634,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "50": {
            "id": 5874669,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "51": {
            "id": 5874670,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "52": {
            "id": 5874671,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "53": {
            "id": 5874672,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "54": {
            "id": 5874673,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "55": {
            "id": 5874706,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "56": {
            "id": 5874735,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "57": {
            "id": 5874736,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "58": {
            "id": 5874737,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "59": {
            "id": 5874738,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "60": {
            "id": 5874739,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "61": {
            "id": 5874740,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "62": {
            "id": 5874741,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "63": {
            "id": 5874742,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "64": {
            "id": 5874743,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "65": {
            "id": 5874744,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "66": {
            "id": 5874745,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "67": {
            "id": 5874814,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "68": {
            "id": 5874823,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "69": {
            "id": 5874643,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "70": {
            "id": 5874644,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "71": {
            "id": 5874645,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "72": {
            "id": 5874646,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "73": {
            "id": 5874684,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "74": {
            "id": 5874685,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "75": {
            "id": 5874686,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "76": {
            "id": 5874687,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "77": {
            "id": 5874688,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "78": {
            "id": 5874709,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "79": {
            "id": 5874768,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "80": {
            "id": 5874769,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "81": {
            "id": 5874770,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "82": {
            "id": 5874771,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "83": {
            "id": 5874772,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "84": {
            "id": 5874773,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "85": {
            "id": 5874774,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "86": {
            "id": 5874775,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "87": {
            "id": 5874776,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "88": {
            "id": 5874777,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "89": {
            "id": 5874778,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "90": {
            "id": 5874817,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "91": {
            "id": 5874826,
            "guidelineid": 100414,
            "drugid": "RxNorm:3638",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "imipramine": {
        "0": {
            "id": 5874937,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5874938,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5874939,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5874940,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "4": {
            "id": 5874941,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "5": {
            "id": 5874942,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "6": {
            "id": 5874943,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "7": {
            "id": 5874944,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "8": {
            "id": 5874945,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "9": {
            "id": 5874946,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "10": {
            "id": 5874947,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "11": {
            "id": 5874948,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "12": {
            "id": 5874949,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "13": {
            "id": 5874950,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "14": {
            "id": 5874951,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "15": {
            "id": 5874952,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "16": {
            "id": 5874953,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "17": {
            "id": 5874954,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "18": {
            "id": 5874955,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "19": {
            "id": 5874956,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "20": {
            "id": 5874957,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "21": {
            "id": 5874958,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "22": {
            "id": 5874959,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "23": {
            "id": 5875098,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "24": {
            "id": 5875099,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "25": {
            "id": 5875100,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "26": {
            "id": 5875101,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "27": {
            "id": 5875102,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "28": {
            "id": 5875103,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "29": {
            "id": 5875104,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "30": {
            "id": 5875105,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "31": {
            "id": 5875106,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "32": {
            "id": 5875107,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "33": {
            "id": 5875108,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "34": {
            "id": 5875109,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "35": {
            "id": 5875110,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "36": {
            "id": 5875111,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "37": {
            "id": 5875112,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "38": {
            "id": 5875113,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "39": {
            "id": 5875114,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "40": {
            "id": 5875115,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "41": {
            "id": 5875116,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "42": {
            "id": 5875117,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "43": {
            "id": 5875118,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "44": {
            "id": 5875119,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "45": {
            "id": 5875120,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "46": {
            "id": 5874983,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "47": {
            "id": 5874984,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "48": {
            "id": 5874985,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "49": {
            "id": 5874986,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "50": {
            "id": 5874987,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "51": {
            "id": 5874988,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "52": {
            "id": 5874989,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "53": {
            "id": 5874990,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "54": {
            "id": 5874991,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "55": {
            "id": 5874992,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "56": {
            "id": 5874993,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "57": {
            "id": 5874994,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "58": {
            "id": 5874995,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "59": {
            "id": 5874996,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "60": {
            "id": 5874997,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "61": {
            "id": 5874998,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "62": {
            "id": 5874999,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "63": {
            "id": 5875000,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "64": {
            "id": 5875001,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "65": {
            "id": 5875002,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "66": {
            "id": 5875003,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "67": {
            "id": 5875004,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "68": {
            "id": 5875005,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "69": {
            "id": 5875062,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "70": {
            "id": 5875063,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "71": {
            "id": 5875064,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "72": {
            "id": 5875052,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "73": {
            "id": 5875053,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "74": {
            "id": 5875054,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "75": {
            "id": 5875055,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "76": {
            "id": 5875056,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "77": {
            "id": 5875057,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "78": {
            "id": 5875058,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "79": {
            "id": 5875059,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "80": {
            "id": 5875060,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "81": {
            "id": 5875061,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "82": {
            "id": 5875065,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "83": {
            "id": 5875066,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "84": {
            "id": 5875067,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "85": {
            "id": 5875068,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "86": {
            "id": 5875069,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "87": {
            "id": 5875070,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "88": {
            "id": 5875071,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "89": {
            "id": 5875072,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "90": {
            "id": 5875073,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "91": {
            "id": 5875074,
            "guidelineid": 100414,
            "drugid": "RxNorm:5691",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    },
    "trimipramine": {
        "0": {
            "id": 5875663,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "1": {
            "id": 5875664,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "2": {
            "id": 5875665,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "3": {
            "id": 5875699,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "4": {
            "id": 5875666,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "5": {
            "id": 5875700,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "6": {
            "id": 5875701,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "7": {
            "id": 5875702,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "8": {
            "id": 5875703,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "9": {
            "id": 5875744,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "10": {
            "id": 5875753,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "11": {
            "id": 5875754,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "12": {
            "id": 5875755,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "13": {
            "id": 5875756,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "14": {
            "id": 5875757,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "15": {
            "id": 5875758,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "16": {
            "id": 5875759,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "17": {
            "id": 5875760,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "18": {
            "id": 5875761,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "19": {
            "id": 5875762,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "20": {
            "id": 5875763,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "21": {
            "id": 5875852,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "22": {
            "id": 5875861,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
            },
            "drugrecommendation": "Initiate therapy with recommended starting dose.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "23": {
            "id": 5875691,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "24": {
            "id": 5875692,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "25": {
            "id": 5875693,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "26": {
            "id": 5875694,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "27": {
            "id": 5875734,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "28": {
            "id": 5875735,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "29": {
            "id": 5875736,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "30": {
            "id": 5875737,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "31": {
            "id": 5875738,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "32": {
            "id": 5875751,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "33": {
            "id": 5875830,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "34": {
            "id": 5875831,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "35": {
            "id": 5875832,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "36": {
            "id": 5875833,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "37": {
            "id": 5875834,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "38": {
            "id": 5875835,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "39": {
            "id": 5875836,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "40": {
            "id": 5875837,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "41": {
            "id": 5875838,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "42": {
            "id": 5875839,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "43": {
            "id": 5875840,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "44": {
            "id": 5875859,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "45": {
            "id": 5875868,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "46": {
            "id": 5875671,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "47": {
            "id": 5875672,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "48": {
            "id": 5875673,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "49": {
            "id": 5875674,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "50": {
            "id": 5875709,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "51": {
            "id": 5875710,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "52": {
            "id": 5875711,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "53": {
            "id": 5875712,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "54": {
            "id": 5875713,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "55": {
            "id": 5875746,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "56": {
            "id": 5875775,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "57": {
            "id": 5875776,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "58": {
            "id": 5875777,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "59": {
            "id": 5875778,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "60": {
            "id": 5875779,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "61": {
            "id": 5875780,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "62": {
            "id": 5875781,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "63": {
            "id": 5875782,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "64": {
            "id": 5875783,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "65": {
            "id": 5875784,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "66": {
            "id": 5875785,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "67": {
            "id": 5875854,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "68": {
            "id": 5875863,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
            },
            "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "population": "general",
            "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "69": {
            "id": 5875683,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "70": {
            "id": 5875684,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "71": {
            "id": 5875685,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "72": {
            "id": 5875686,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Intermediate Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "73": {
            "id": 5875726,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "74": {
            "id": 5875727,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "75": {
            "id": 5875728,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "76": {
            "id": 5875724,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "77": {
            "id": 5875725,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Normal metabolism of TCAs",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Strong",
            "phenotypes": {
                "CYP2D6": "Normal Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "1.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "78": {
            "id": 5875749,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Poor Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "0.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "79": {
            "id": 5875808,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "80": {
            "id": 5875809,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "3.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "81": {
            "id": 5875810,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "2.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "82": {
            "id": 5875811,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "4.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "83": {
            "id": 5875812,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "84": {
            "id": 5875813,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "85": {
            "id": 5875814,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "86": {
            "id": 5875815,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "87": {
            "id": 5875816,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "88": {
            "id": 5875817,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "89": {
            "id": 5875818,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Ultrarapid Metabolizer",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "90": {
            "id": 5875857,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "Indeterminate",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        },
        "91": {
            "id": 5875866,
            "guidelineid": 100414,
            "drugid": "RxNorm:10834",
            "implications": {
                "CYP2D6": "n/a",
                "CYP2C19": "n/a"
            },
            "drugrecommendation": "No recommendation",
            "classification": "Optional",
            "phenotypes": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "activityscore": {
                "CYP2D6": "No Result",
                "CYP2C19": "n/a"
            },
            "allelestatus": {},
            "lookupkey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "population": "general",
            "comments": "n/a",
            "version": 1,
            "dosinginformation": false,
            "alternatedrugavailable": false,
            "otherprescribingguidance": false
        }
    }
}